Clinical trial
Assessment of the Effects and Tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v Eye Drops Solution) for the Treatment of Bacterial Conjunctivitis in Adults: a Multicentre, Randomized, Blinded-assessor, Phase II Non Inferiority Study - MIRAKLE
NCT06616922 is registered in ClinicalTrials.gov with NTC srl as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of the Effects and Tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v Eye Drops Solution) for the Treatment of Bacterial Conjunctivitis in Adults: a Multicentre, Randomized, Blinded-assessor, Phase II Non Inferiority Study - MIRAKLE
- Lead sponsor
- NTC srl
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 5, 2021
- Completion date
- September 19, 2023
- Enrollment
- 252 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.